A 10-Year Study Confirms Longer Survival with Multimodal Therapy
Multimodal therapy may give patients the best odds of surviving mesothelioma. Multimodal therapy often includes surgery, chemotherapy and radiation. A new article in the Journal of Chest Surgery detail the results of a new analysis of mesothelioma survival. Many Mesothelioma Therapies Malignant mesothelioma is a rare and aggressive cancer that rarely responds to a single cancer therapy. Malignant mesothelioma is almost always caused by exposure to asbestos. Usually, that happens in the workplace. Because mesothelioma is such a difficult cancer to treat, doctors often take a multi-faceted approach. This includes combining surgery, chemotherapy, and radiation. Yet even when combined, these therapies achieve only minimal success. And patients often face a grim prognosis. The 5-year survival rate of patients with mesothelioma … Continue reading A 10-Year Study Confirms Longer Survival with Multimodal Therapy
Localized Mesothelioma Successfully Treated with Chemotherapy and Surgery
A patient with a rare, localized malignant pleural mesothelioma has been successfully treated. The patient received chemotherapy and surgery and has been disease-free for 12 months. Many believe that a localized form of pleural mesothelioma might have a better survival outlook. This is compared with patients who have the more common, diffuse variety. This latest report comes from a Japanese team of thoracic surgeons. Local vs. Diffuse Mesothelioma Malignant mesothelioma is a rare cancer affecting an estimated 2,500 Americans annually. All forms of mesothelioma have been linked to asbestos exposure. Malignant pleural mesothelioma is the most common form of malignant mesothelioma. Most pleural mesothelioma patients have a type of cancer that tends to spread quickly. It spreds across the thin membrane … Continue reading Localized Mesothelioma Successfully Treated with Chemotherapy and Surgery
Easing the Painful Symptoms of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma is an aggressive and rare cancer. There is new hope for reducing the painful symptoms of malignant pleural mesothelioma. A new study in BMC Cancer looked at treatments and the symptom burden of malignant pleural mesothelioma in Europe. The symptoms of malignant pleural mesothelioma are very hard. But there are treatments available to improve quality of life. New data proves that chemotherapy eases mesothelioma symptoms. And it is most likely to improve and maintain health-related quality of life. The Long Journey of Mesothelioma Mesothelioma is the asbestos-caused cancer. Malignant pleural mesothelioma is the most common form of mesothelioma. It accounts for over 90,000 deaths per year globally. It takes a very long time to diagnose mesothelioma. Usually, … Continue reading Easing the Painful Symptoms of Malignant Pleural Mesothelioma
Treatment Protocol of an 8-Year Survivor of Mesothelioma
A new article in Scholars Journal of Medical Case Reports outlines the treatment protocol of an 8-year survivor of mesothelioma. Malignant pleural mesothelioma is difficult to treat. This aggressive cancer is caused by asbestos exposure and is resistant to most standard cancer therapies, including radiotherapy. Many people diagnosed with mesothelioma die within a few months to a year. Paul Kraus is considered the longest documented survivor of mesothelioma in the world. He was diagnosed in 1997 and was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic lifestyle changes, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. … Continue reading Treatment Protocol of an 8-Year Survivor of Mesothelioma
Second Treatment Course May Increase Mesothelioma Patient Survival
Oncologists report that a second treatment course may be a good option for some mesothelioma patients. Almost all mesothelioma patients experience progression after the first treatment. Recommendations for a second treatment are still unclear. There is very limited information available on second and repeat treatments. Pemetrexed combined with platinum-based chemotherapy is a standard first treatment for mesothelioma. A report in BMC Cancer says that a repeat treatment may be good for eligible patients. In this study, patients who received a second treatment of chemotherapy survived longer. Understanding Second Treatments or Retreatments Malignant pleural mesothelioma is a rare, aggressive cancer linked to asbestos exposure. There have been several recent treatment advances. But the mesothelioma prognosis is still poor with an average … Continue reading Second Treatment Course May Increase Mesothelioma Patient Survival
Predicting How a Patient Will Respond to Mesothelioma Treatment
Malignant pleural mesothelioma is a rare cancer. Early diagnosis is challenging. Treatments are the first clinical option in the advanced disease stage. A doctor’s initial clinical response says a lot about the patient’s prognosis. It may even represent a useful way to identify patients with a better long-term outcome. A new Italian study from the Journal of Clinical Medicine looks at this possibility. First Mesothelioma Treatment Response Options Scientists looked at the initial treatment response in 46 mesothelioma patients who had pleural mesothelioma. None of these patients had surgery as an option because their tumors were considered inoperable. The doctor’s initial treatment response included a CT scan and clinical examination. This examination was usually after 2–3 cycles of drug therapy. … Continue reading Predicting How a Patient Will Respond to Mesothelioma Treatment
First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy
A recent study compared mesothelioma patients’ survival by physician’s choice of treatment. Is first-line chemotherapy the best choice? Malignant pleural mesothelioma is an aggressive cancer that affects older adults. Mesothelioma patients often have other comorbidities making real-world treatment decisions challenging. The first was by choice of first-line chemotherapy. The second was the physician’s choice of second-line chemotherapy versus immunotherapy. And the third was by the physician’s choice of use of maintenance therapy. Physician’s Choice of First-Line Chemotherapy Drugs This is the largest real-world study of U.S. patients diagnosed with mesothelioma. Scientists analyzed physicians’ choice of first-line chemotherapy, second-line therapy, and maintenance therapy. In the first-line chemotherapy analysis, there was no significant difference in patient survival. As of this writing, the only … Continue reading First-Line Chemotherapy versus Immunotherapy versus Maintenance Therapy
Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma
Nivolumab + ipilimumab continues to provide a long-term survival benefit in malignant pleural mesothelioma. A new report shows a 3-year follow-up in the CheckMate Clinical Trial. Long-term clinical benefits remained the same for all patient groups. Background on the Nivolumab + Ipilimumab Treatment Two years ago, the FDA approved the combination of nivolumab + ipilimumab. It is the first-line treatment for patients with metastatic non-small cell lung cancer. The CHECKMATE randomized multi-part trial investigated the effectiveness. The trial showed a significant improvement in patient survival. Today, this treatment combination improves patient survival rates over chemotherapy. Mesothelioma patients showed an improved survival using this line of treatment. A new report from the Annals of Oncology describes updated data with at least … Continue reading Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma
New Artificial Intelligence Tool Measures Mesothelioma Tumors
A new artificial intelligence tool can measure mesothelioma tumors without any human input. Automated mesothelioma tumor measurement is now possible. The artificial intelligence algorithm performed well. There were 266 malignant pleural mesothelioma tumors analyzed. This is the largest study of its kind performed in mesothelioma. And this is the first description of an automated artificial intelligence tool. Inconsistent Mesothelioma Measurement During Clinical Assessment In malignant pleural mesothelioma, complex tumors result in inconsistent clinical assessment. Promising new methods need practical computer automation methods. A new publication showed an automated tool for this purpose. This study compared a new artificial intelligence tool with human standard clinical assessment. This study looked at mesothelioma patients treated with chemotherapy. Evaluating How Well the New Tool … Continue reading New Artificial Intelligence Tool Measures Mesothelioma Tumors
Bevacizumab: An Immune Therapy in Mesothelioma Treatment
Bevacizumab, an immune therapy, enhances the immune system to target cancer cells. Historically, chemotherapy drugs were considered the standard treatment. But, a new study highlights bevacizumab, an immune therapy. It can now be considered in combination with mesothelioma treatments where accessible. Chemotherapy has been a popular treatment therapy. Cytotoxic chemotherapy uses anti-cancer (cytotoxic) drugs to destroy cancer cells. It results in a modest improvement in patient survival. But toxicity limits the eligible patient population. Targeted Chemotherapy Agents Immunotherapies are now playing a greater role in the treatment of many cancers. The last decade has presented a paradigm shift. There has been a change in the way we understand the relationship between the immune system and cancer progression. Several targeted agents … Continue reading Bevacizumab: An Immune Therapy in Mesothelioma Treatment
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!